Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. (NYSE: QGEN) concerning potential violations of the federal securities laws.
During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: “You will see QuantiFERON picking up in Q2 … accelerating to achieve … between 6% and 7% growth” in 2026. He noted Qiagen’s projections remained “perfectly aligned with the target that we gave during our Capital Market Day in June 2024.” On April 28, 2026, Qiagen walked back on these claims and CFO Roland Sackers revealed the disappointing guidance: sales were now projected to “continue at a largely unchanged level from the second quarter of 2025,” and investors would have to wait for QuantiFERON to “return to a more normalized growth rate in 2027.”
If you suffered a loss on your Qiagen N.V. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





